OASIS Project 1: Development of a text message-based approach to depression screening for cancer survivors

Date Added
May 30th, 2025
PRO Number
Pro00143112
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer
Summary

Depression is common among cancer survivors, but current ways to address this area of care are lacking. In this project, we will work with cancer survivors and oncology providers to build a text-message based approach to screen cancer survivors for depression. Long term, we hope this research can be used to improve screening for depression for cancer survivors

Institution
MUSC
Recruitment Contact
Nivetha Baskar
843-792-0719
baskar@musc.edu

Sex differences in the genetics of cannabinoid metabolism

Date Added
May 29th, 2025
PRO Number
Pro00144812
Researcher
Erin Martin

List of Studies

Keywords
Substance Use
Summary

This study will examine genetic factors that contribute to the different ways people feel after consuming cannabis. People that use cannabis at least 4 days per week will participate in a study involving 1 in-person visit followed by a 5-day remote assessment period. The in-person visit will determine if an individual is eligible for study participation and their blood will be drawn to assess genetics. During the remote assessment period, participants will complete multiple short surveys per day describing their feelings and their recent cannabis use.

Institution
MUSC
Recruitment Contact
Erin Martin
843-876-3528
marterin@musc.edu

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Date Added
May 29th, 2025
PRO Number
Pro00139971
Researcher
Lara Wine Lee

List of Studies


Keywords
Skin
Summary

An international research registry called the CorEvitas International Adolescent Alopecia Areata (AA) Registry (the "CorEvitas Registry"). This observational registry studies adolescent patients with AA between 12-17 years of age under the care of a dermatology provider diagnosed with moderate to severe alopecia areata.

Institution
MUSC
Recruitment Contact
Mary Tyler Lillich
843-876-9302
lillich@musc.edu

A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

Date Added
May 27th, 2025
PRO Number
Pro00143751
Researcher
Daniel Silverman

List of Studies

Keywords
Cardiovascular, Pulmonary Hypertension
Summary

The purpose of the study is to evaluate the safety and how well the medication sotatercept works versus placebo in treating Heart Failure with a Preserved Ejection Fraction. The study will also look at information obtained from the tests performed as part of the study to see if subjects have improvement in symptoms of heart failure. Participation in this study will last approximately 26 months. During the study period subjects will be asked to attend regular study visits with the research coordinator. These visits will include such activities as blood tests, questionnaires, physical evaluation by a study doctor, a right heart catheterization with exercise, echocardiogram, and 6 minute hall walks. There will be 35 visits as part of participation in this clinical trial.

Participants will be randomized to either the treatment group (and receive the medication) or the control group (and not receive the medication). Subjects will have a 2:1 chance of receiving the study medication during their participation in the trial. The treatment assignment is determined by randomization, where a computer selects at random which treatment group you will be in (like drawing straws). Neither the subject, nor the blinded personnel will know which group subjects are in. Neither the subject nor the study doctor will decide what group subjects are assigned. Participants from the placebo group in CADENCE who enter HARMONIZE at Visit 9a will be randomized 1:1 to one of the active treatment groups. Participants from an active treatment group in CADENCE entering HARMONIZE after Visit 9a will be allocated to continue in the same treatment group (ie, sotatercept dose level) as in CADENCE.

Institution
MUSC
Recruitment Contact
Madison Johnson
843-792-4615
johme@musc.edu

Statin use, cholesterol control and prostate cancer tumor metabolism

Date Added
May 23rd, 2025
PRO Number
Pro00144135
Researcher
Michael Marrone

List of Studies

Keywords
Cholesterol, Disease Prevention, Prostate
Summary

Profound racial inequities in statin use and cholesterol control mirror racial disparities in prostate cancer, where Black men are less likely to use a statin and have worse cholesterol control, are 78% more likely to be diagnosed with prostate cancer, and twice as likely to die from the disease compared to White men. Despite these parallels, the role of cholesterol control in prostate cancer racial disparities is poorly understood. Here, we investigate whether inequities in cholesterol control between Black and White men not using statins compared to cholesterol control in statin users contribute to prostate cancer racial disparities through interactions with tumor metabolism and the tumor microenvironment (TME), a novel concept supported by strong rationale.

Institution
MUSC
Recruitment Contact
NA
NA
NA

Adolescent Perspectives on Adapting Written Exposure Therapy for Adolescents with PTSD

Date Added
May 21st, 2025
PRO Number
Pro00144898
Researcher
Emily Tilstra-Ferrell

List of Studies

Keywords
Adolescents
Summary

The proposed research will qualitatively examine adolescent perspectives on adapting Written Exposure Therapy (WET), an evidence-based treatment for posttraumatic stress disorder (PTSD) among adults, for use with adolescents. The present study will take the first step in adapting WET for adolescents by conducting interviews with adolescents with PTSD. Interview questions will focus on identifying perceptions of WET and recommendations for adapting WET for the needs of adolescents. A brief survey will also be conducted. Participation in the interview and survey will involve a one-time study visit that lasts up to 60 minutes and can be conducted in person or virtually. Adolescent participants need be accompanied by a caregiver either in person or virtually.

Institution
MUSC
Recruitment Contact
Emily Tilstra-Ferrell
843-471-0302
ferrelle@musc.edu

Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial

Date Added
May 20th, 2025
PRO Number
Pro00143653
Researcher
Brian Orr

List of Studies

Keywords
Cancer, Cancer/Genitourinary, Cancer/Other, Drug Studies, Women's Health
Summary

This study is for patients that have been diagnosed with ovarian cancer who are taking bevacizumab. This study is testing two investigational drugs called nelfinavir and hydroxychloroquine. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA) for the treatment of cancer. The primary purpose of this study is to see if these two medications in combination with bevacizumab are safe and effective in ovarian cancer. These drugs will be given by mouth. Participants in this study can expect to be in this study for 6 months for data collection, but may continue on the study medications longer if seeing benefit.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A pragmatic remote approach to improve transitions of care and retention in opioid use disorder treatment: Qualitative Interviews

Date Added
May 20th, 2025
PRO Number
Pro00141967
Researcher
Allison Smith

List of Studies


Keywords
Psychiatry, Substance Use
Summary

The primary objective of this proposal is to conduct surveys and qualitative interviews to get feedback from (1) stakeholders and (2) people with lived experience of opioid use and a related medical hospitalization, on the barriers and facilitators of new potential strategy of treatment. The potential proposed intervention we will ask questions about is the direct mailing medications for opioid use disorder (OUD) in an attempt to overcome many of the barriers that interfere with treatment retention (i.e. transportation). Qualitative interviews will be used to get feedback on the feasibility, appropriateness, and acceptability of mailing maintenance medications for OUD after a hospital discharge. In a future study, this feedback will be used to develop a protocol to test this method.

Institution
MUSC
Recruitment Contact
Allison Smith
843-792-0686
smithall@musc.edu

Investigation of a Novel, magNetically levitated VAD for the treatment of refractOry left Ventricular heArT failurE (INNOVATE Trial)

Date Added
May 15th, 2025
PRO Number
Pro00143150
Researcher
Arman Kilic

List of Studies

Keywords
Cardiovascular, Heart, Surgery
Summary

The objective of the study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3™ (HM3) LVAS (Abbott) when used for the treatment of advanced, refractory, left ventricular heart failure.

Institution
MUSC
Recruitment Contact
Deanna DeHoff
(843) 792-8522
dehoff@musc.edu

A PROSPECTIVE, MULTICOUNTRY STUDY TO ESTIMATE THE INCIDENCE OF AND PROVIDE A BEST PRACTICE MODEL FOR MONITORING THE DEVELOPMENT OF POST-STROKE SPASTICITY

Date Added
May 15th, 2025
PRO Number
Pro00142456
Researcher
Parneet Grewal

List of Studies

Keywords
Stroke, Stroke Recovery
Summary

This study is looking for participants who have had a stroke for the first time and have also had weakness (known as "paresis") in their arms or legs. People who have weakness in their arms or legs after their stroke are at risk of developing spasticity. Spasticity is a condition where muscles stiffen or tighten involuntarily, preventing normal movement, and sometimes causing discomfort or pain.

This study is looking at the proportion of first-ever stroke participants with paresis who develop spasticity up to 12 months after their stroke. We would like to do this by contacting you regularly to see whether you have developed spasticity. The study period for each individual participant will vary depending on whether and when spasticity or problematic spasticity develops.

Institution
MUSC
Recruitment Contact
Caitlan LeMatty
843-792-8606
lemattyc@musc.edu



-- OR --